Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation

Br J Haematol. 2021 Mar;192(6):e148-e151. doi: 10.1111/bjh.17365. Epub 2021 Feb 22.

Affiliations

¹ Department of Medicine A, Haematology, Oncology, University Hospital Muenster, Muenster, Germany.
² Philogen S.p.A., Siena, Italy.
³ Department of Paediatric Oncology and Haematology, University Children´s Hospital Muenster, Muenster, Germany.
⁴ Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany.

^# Contributed equally.

PMID: 33618424
DOI: 10.1111/bjh.17365

No abstract available

Publication types

Clinical Trial, Phase I
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Allografts
Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Cytarabine / administration & dosage
Female
Hematopoietic Stem Cell Transplantation*
Humans
Interleukin-2 / administration & dosage
Leukemia, Myeloid, Acute / diagnostic imaging
Leukemia, Myeloid, Acute / mortality
Leukemia, Myeloid, Acute / therapy*
Male
Middle Aged
Recombinant Fusion Proteins / administration & dosage

Substances

Antineoplastic Agents, Immunological
IL2 protein, human
Interleukin-2
Recombinant Fusion Proteins
Cytarabine

Grants and funding